Duloxetine hydrochloride + placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Diabetic Neuropathy, Painful

Conditions

Diabetic Neuropathy, Painful

Trial Timeline

Oct 1, 2002 → Mar 1, 2005

NCT ID

NCT00058968

About Duloxetine hydrochloride + placebo

Duloxetine hydrochloride + placebo is a phase 3 stage product being developed by Eli Lilly for Diabetic Neuropathy, Painful. The current trial status is completed. This product is registered under clinical trial identifier NCT00058968. Target conditions include Diabetic Neuropathy, Painful.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00673452	Approved	Completed	Jun 1, 2008	Jul 1, 2009	Fibromyalgia
NCT00536471	Approved	Completed	Sep 1, 2007	Dec 1, 2008	Major Depressive Disorder
NCT00422162	Approved	Completed	Feb 1, 2007	Aug 1, 2008	Major Depressive Disorder
NCT00408993	Phase 3	Completed	Dec 1, 2006	Feb 1, 2008	Diabetic Neuropathies
NCT00406848	Approved	Completed	Nov 1, 2006	Nov 1, 2009	Major Depressive Disorder
NCT00244296	Approved	Completed	Oct 1, 2005	Jan 1, 2007	Urinary Incontinence, Stress
NCT00191919	Phase 3	Completed	May 1, 2005	May 1, 2006	Depressive Disorder, Major
NCT00122863	Phase 3	Completed	Jan 1, 2005	Mar 1, 2007	Anxiety Disorders
NCT00122824	Phase 3	Completed	Jun 1, 2004	Sep 1, 2005	Anxiety Disorders
NCT00190996	Phase 3	Completed	Jan 1, 2003	Jun 1, 2006	Urinary Incontinence, Stress
NCT00058968	Phase 3	Completed	Oct 1, 2002	Mar 1, 2005	Diabetic Neuropathy, Painful

Competing Products

20 competing products in Diabetic Neuropathy, Painful

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	44
CHF6467 active	Comac Medical	Phase 1/2	33
Ruboxistaurin mesylate	Eli Lilly	Phase 3	77
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	47
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	28
Baricitinib + Placebo	Eli Lilly	Phase 2	52
LY3857210 + Placebo	Eli Lilly	Phase 2	52
UBX1325	Unity Biotechnology	Phase 2	44
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	44
UBX1325	Unity Biotechnology	Phase 1	25
CT-P42 + Eylea	Celltrion	Phase 3	77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	85
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	85
CS-3150 + placebo	Daiichi Sankyo	Phase 2	52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	52
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	77
DS-5565 + placebo	Daiichi Sankyo	Phase 3	77
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	77
DS-5565	Daiichi Sankyo	Phase 3	77
Beraprost sodium	Astellas Pharma	Pre-clinical	23

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved